Artiva Biotherapeutics Pivots to Rheumatoid Arthritis at TD Cowen, Teases 2026 RA Data Update [Yahoo! Finance]
Artiva Biotherapeutics, Inc. (ARTV)
Company Research
Source: Yahoo! Finance
an ACR50 of ~50% at six months in patients after failure of two targeted therapies and expects to interact with the FDA and share RA data on =15 patients in the first half of 2026 The company's non-genetic, antibody-mediated allogeneic NK platform uses selected umbilical cord units to produce thousands of cryopreserved, infusion-ready vials per unit, saying capacity could treat ~1,000 patients at its San Diego site and projecting a COGS of $1,000 or less per vial Early safety and pharmacology signals in 32 autoimmune patients showed no CRS/ICANS , low hospitalization, and deep B-cell depletion by a high-sensitivity assay, and Artiva reported $123 million cash providing runway into Q2 2027 Interested in Artiva Biotherapeutics, Inc.? Here are five stocks we like better. Artiva Biotherapeutics (NASDAQ:ARTV) used a presentation and fireside chat at TD Cowen's 46th Annual Healthcare Conference to outline its strategy in “deep B-cell depletion” for autoimmune disease, emphasizing rh
Show less
Read more
Impact Snapshot
Event Time:
ARTV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARTV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARTV alerts
High impacting Artiva Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ARTV
News
- Latigo Biotherapeutics Appoints Neha Krishnamohan as Chief Financial Officer and Chief Business Officer [Yahoo! Finance]Yahoo! Finance
- Artiva Biotherapeutics to Participate in the TD Cowen 46th Annual Health Care Conference [Yahoo! Finance]Yahoo! Finance
- Artiva Biotherapeutics to Participate in the TD Cowen 46th Annual Health Care ConferenceGlobeNewswire
- Artiva Biotherapeutics Announces Appointment of Thad Huston as Chief Financial Officer and Award of Inducement GrantGlobeNewswire
- Artiva Biotherapeutics Announces Appointment of Elaine Sorg to Board of DirectorsGlobeNewswire
ARTV
Sec Filings
- 2/24/26 - Form 3
- 2/24/26 - Form 8-K
- 2/19/26 - Form 4
- ARTV's page on the SEC website